Having received a lot of feedback, Russia have issued an updated version of their concept paper. It appears that some of the feedback has been taken into account, but the result is still a very complex implementation, with much detail still to be resolved.

Below are some of the “headlines” as I see them from the updated concept paper. Please forgive me if you interpret what is said in the paper differently, but as usual with this sort of evolving and complex legislation, there is plenty of room for ambiguity and interpretation.

The overall system is referred to as the FGIS MDLP, or the system for the monitoring of movement of drugs from manufacturer to end consumer

Purpose

To guarantee the supply of high quality, effective and safe medicines

There is also a lot of language and functionality described to monitor and control drug pricing throughout the supply chain